Roche Holding AG


Kursmål for aktien: 271.95 CHF

Det gennemsnitlige kursmål for Roche Holding AG aktien er 271.95 CHF hvilket viser forventningen til aktien indenfor de næste 12 mdr. aktien er undervurderet, da kursmålet ligger under det aktuelle aktiekurs. Aktien er undervurderet med 9,83 % Aktien forventes derfor at stige og være en god investering.

Om Roche Holding AG aktien

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, the company supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. It has collaboration with Gilead Sciences, Inc. for COVID-19; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company also has a collaboration with Bristol Myers Squibb to advance personalized healthcare through digital pathology solutions. The company was founded in 1896 and is headquartered in Basel, Switzerland. Læs mere
CHF 200B Markedsværdi (Mcap)
CHF 60,4B Omsætning
Drug Manufacturers - General Industri
Schweiz Handles på børsen Hjemmeside
Sundhed Sektor